Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab for Palmoplantar Non-Pustular Psoriasis (Phase 3b)
2018-003206-58Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriasis comparing Guselkumab with Placebo (2 arms). Primary endpoint: ppPASI75 response at Week 16. Started Apr 2019; status: completed.
02
Drugs
guselkumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2018-003206-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003206-58.